Comprehensive Review of AL amyloidosis: some practical recommendations

Autor: Florent Malard, Jean-Luc Harousseau, Ali Bazarbachi, Abdul Hamid Bazarbachi, Mohamad Mohty, Rama Al Hamed
Přispěvatelé: Albert Einstein College of Medicine [New York], American University of Beirut [Beyrouth] (AUB), Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, CRLCC René Gauducheau, Gestionnaire, Hal Sorbonne Université, Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Oncology
medicine.medical_specialty
Amyloid
[SDV]Life Sciences [q-bio]
Antineoplastic Agents
Review Article
Plasma cell
Transplantation
Autologous
Bortezomib
03 medical and health sciences
0302 clinical medicine
Autologous stem-cell transplantation
Internal medicine
medicine
AL amyloidosis
Animals
Humans
Immunoglobulin Light-chain Amyloidosis
1234567890()
RC254-282
business.industry
Amyloidosis
Daratumumab
Disease Management
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Hematology
medicine.disease
3. Good health
[SDV] Life Sciences [q-bio]
medicine.anatomical_structure
Combination drug therapy
Disease Presentation
030220 oncology & carcinogenesis
Immunotherapy
Neoplasm Recurrence
Local
business
Haematological diseases
030215 immunology
medicine.drug
Stem Cell Transplantation
Zdroj: Blood Cancer Journal, Vol 11, Iss 5, Pp 1-13 (2021)
Blood Cancer Journal
Blood Cancer Journal, 2021, 11 (5), pp.97. ⟨10.1038/s41408-021-00486-4⟩
Blood Cancer Journal, Nature Publishing Group, 2021, 11 (5), pp.97. ⟨10.1038/s41408-021-00486-4⟩
ISSN: 2044-5385
DOI: 10.1038/s41408-021-00486-4⟩
Popis: Amyloid light chain (AL) amyloidosis is among the more common and more severe of the amyloidoses usually involving the slow proliferation of a bone-marrow-residing plasma cell (PC) clone and the secretion of unstable immunoglobulin-free light chains (FLC) that infiltrate peripheral tissues and result in detrimental end-organ damage. Disease presentation is rather vague, and the hallmark of treatment is early diagnosis before irreversible end-organ damage. Once diagnosed, treatment decision is transplant-driven whereby ~20% of patients are eligible for autologous stem cell transplantation (ASCT) with or without bortezomib-based induction. In the setting of ASCT-ineligibility, bortezomib plays a central role in upfront treatment with the recent addition of daratumumab to the current emerging standard of care. In general, management of AL amyloidosis is aimed at achieving deep, durable responses with very close monitoring for early detection of relapse/refractory disease. This article provides a comprehensive review of the management of patients with AL amyloidosis including goals of therapy, current treatment guidelines in the setting of both ASCT-eligibility and ineligibility, treatment response monitoring recommendations, toxicity management, and treatment of relapse/refractory disease.
Databáze: OpenAIRE
Externí odkaz: